Vectura Group plc Notice of Interim Results (2146M)
July 27 2017 - 1:03AM
UK Regulatory
TIDMVEC
RNS Number : 2146M
Vectura Group plc
27 July 2017
Vectura Group plc
Notice of Interim Results
Chippenham, UK, 27 July 2017: Vectura Group plc (LSE: VEC) ("the
Group"), an industry-leading inhaled airways disease focused
business, plans to announce its Interim Results for the six-month
period ending 30 June 2017 on Wednesday 6 September 2017.
James Ward-Lilley, Chief Executive Officer, and Andrew Derodra,
Chief Financial Officer, will host a briefing for analysts at
9.30am on the morning of the results at the offices of Numis
Securities Ltd., 10 Paternoster Square, London, EC4M 7LT.
A live webcast of the meeting, with the presentation slides,
will be available on Vectura's website:
http://www.vectura.com/investors/presentations-webcasts/.
- ENDS -
For more information, please contact:
Vectura Group plc +44 (0)1249 667700
Andrew Derodra - Chief Financial Officer
Fleur Wood - Director Communications
Elizabeth Knowles - Director Investor Relations and Analysis
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange
(LSE: VEC), is an industry-leading device and formulation business
for inhaled airways products offering a uniquely integrated inhaled
drug delivery platform. With our extensive range of device and
formulation technologies, integrated capabilities and
collaborations, we are a leader in the development of inhalation
products, increasing our ability to help patients suffering from
respiratory diseases.
Vectura has eight inhaled, four non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a portfolio of drugs in clinical development, a number of which
have licence agreements with several global pharmaceutical and
biotechnology companies including Hikma, Novartis, Sandoz,
Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer,
Chiesi, Almirall, Janssen, and Tianjin KingYork. For further
information, please visit Vectura's website at www.vectura.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOROKADKOBKDQOB
(END) Dow Jones Newswires
July 27, 2017 02:03 ET (06:03 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024
